Gsk (GSK) Non-Current Debt (2009 - 2026)

Gsk (GSK) has 18 years of Non-Current Debt data on file, last reported at -$18.7 billion in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt rose 8.35% year-over-year to -$18.7 billion; the trailing twelve-month figure through Jun 2026 stood at -$18.7 billion (up 8.35% YoY), and the FY2025 full-year result was -$19.6 billion, down 4.56% from the prior year.
• Non-Current Debt was -$18.7 billion for Q2 2026 at Gsk, up from -$18.9 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of -$12.6 billion in Q1 2022 to a low of -$23.7 billion in Q2 2022.
• A 5-year average of -$19.4 billion and a median of -$19.5 billion in 2025 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt surged 60.47% in 2022 and sank 61.03% in 2023, its largest moves.
• Gsk's Non-Current Debt stood at -$20.0 billion in 2022, then increased by 5.55% to -$18.9 billion in 2023, then climbed by 0.45% to -$18.8 billion in 2024, then decreased by 4.14% to -$19.6 billion in 2025, then gained by 4.35% to -$18.7 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were -$18.7 billion in Q2 2026, -$18.9 billion in Q1 2026, and -$19.6 billion in Q4 2025.